Targeting antiviral pathway may offer a new approach to figh

Targeting part of an antiviral pathway triggered by the accumulation of a key pathogen shared in Alzheimer's disease and frontotemporal dementia may one day offer a new therapeutic approach to deterring or delaying cognitive decline, according to preclinical research led by Weill Cornell Medicine scientists.

Related Keywords

Judithb Resnick , Sadaf Amin , Yige Huang , Emily Henderson , Robert Appel Alzheimer Disease Research Institute , Weill Cornell Graduate School Of Medical Sciences , Weill Cornell Medicine , Nature Neuroscience , Robert Appel Alzheimer , Disease Research Institute , Distinguished Professor , Neurodegenerative Diseases , Weill Cornell , Appel Alzheimer , Weill Cornell Graduate School , Medical Sciences , Dementia , Frontotemporal Dementia , Lzheimer 39s Disease , Rain , Fell , Na , Nzyme , Gene , Enome , Immune System , Immunity , Interferon , Medicine , Icroglia , Eurons , Neuroscience , Athogen , Reclinical , Protein , Research , Tau Protein ,